Tourmaline Bio Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Tourmaline Bio Inc
Access all reports
Tourmaline Bio Inc. is a biotechnology company focused on developing treatments for immune and inflammatory diseases. The company is engaged in the late-stage clinical development of therapies aimed at significantly improving the lives of patients with severe autoimmune and inflammatory conditions. Its product pipeline includes medicines designed to address conditions such as atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
TRML
Country
🇺🇸 United States